Los Angeles Capital Management LLC purchased a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) in the 1st quarter, Holdings Channel reports. The fund purchased 93,417 shares of the company’s stock, valued at approximately $720,000.
Other large investors have also modified their holdings of the company. Signaturefd LLC boosted its stake in Travere Therapeutics by 1,656.4% during the 4th quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after purchasing an additional 2,849 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Travere Therapeutics by 968.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock valued at $51,000 after buying an additional 5,121 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Travere Therapeutics by 353.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock worth $78,000 after buying an additional 6,773 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Travere Therapeutics in the 4th quarter worth approximately $137,000. Finally, Virtu Financial LLC acquired a new stake in Travere Therapeutics in the 4th quarter valued at approximately $175,000.
Travere Therapeutics Stock Up 6.6 %
Shares of NASDAQ:TVTX opened at $7.79 on Tuesday. The company has a debt-to-equity ratio of 5.10, a quick ratio of 2.75 and a current ratio of 2.78. Travere Therapeutics, Inc. has a 1-year low of $5.12 and a 1-year high of $17.57. The company has a 50 day moving average price of $6.59 and a 200 day moving average price of $7.72.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on TVTX shares. Canaccord Genuity Group boosted their price target on Travere Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Guggenheim reaffirmed a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. HC Wainwright reissued a “buy” rating and set a $19.00 target price on shares of Travere Therapeutics in a research note on Tuesday, May 7th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $13.00 price target on shares of Travere Therapeutics in a research note on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $15.58.
Read Our Latest Analysis on Travere Therapeutics
Travere Therapeutics Profile
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Read More
- Five stocks we like better than Travere Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- The Top 3 Sectors Poised For Growth This Summer
- Conference Calls and Individual Investors
- U.S. Steel Stock: Betting on EPS Cut and Merger Uncertainty?
- Investing in the High PE Growth Stocks
- GitLab Stock: Pioneering the AI-Powered DevSecOps Platform
Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report).
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.